Werewolf Therapeutics Shares Jump 120% Following Ambros Merger News

By EC Assets · Published 21 August 2026

Werewolf Therapeutics stock surged 120% following news of a merger deal with Ambros Therapeutics. This development significantly impacted the biopharmaceutical company's shares. The merger involves two firms with distinct therapeutic focuses. Ambros Therapeutics previously launched with $125 million in Series A financing. This funding was intended to advance neridronate through a Phase 3 registrational program for Complex Regional Pain Syndrome Type 1. The U.S. Food and Drug Administration (FDA) has granted neridronate Breakthrough Therapy, Fast Track, and Orphan Drug designations. Ambros Therapeutics started its pivotal CRPS-RISE Phase 3 clinical trial of neridronate in patients with Complex Regional Pain Syndrome Type 1 in the first quarter of 2026. Jay Hagan serves as Ambros Therapeutics' Chief Executive Officer. The company also appointed Cris Calsada as Chief Financial Officer and Claire Padgett, Ph.D. as Senior Vice President of Clinical Operations and Program Management on June 11, 2026. Werewolf Therapeutics focuses on an innovative biopharmaceutical approach. The company presented data expanding its PREDATOR® platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting on November 7, 2025. Werewolf Therapeutics is headquartered in Watertown, Massachusetts. The merger highlights consolidation and strategic alliances within the biopharmaceutical sector. These types of transactions often aim to combine pipelines, expertise, and financial resources. Investors are watching how the combined entity will proceed with its clinical programs. This article is intended for informational purposes only. It does not constitute investment advice.